相关实验视频

Updated: Jun 26, 2025

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

在人类中诱导异构的HIV-1中和抗体B细胞系

Wilton B Williams¹, S Munir Alam², Gilad Ofek³

¹Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA; Department of Integrative Immunobiology, Duke School of Medicine, Durham, NC 27710, USA.

|May 18, 2024

概括

一种新的艾滋病毒疫苗方法迅速诱导人类强大的广泛中和抗体 (bnAbs). 这一突破为开发有效艾滋病毒疫苗提供了前景.

科学领域:

免疫学
疫苗学
病毒学

背景情况:

由于难以诱导广泛中和抗体 (bnAbs),开发艾滋病毒疫苗具有挑战性.
在HIV-1患者中,bnAbs通常需要数年才能自然发育.
现有的疫苗策略一直在努力引起有效的HIV-1中和所需的B细胞反应.

研究的目的:

评估一种针对特定B细胞系的新/脂质体免疫原.
调查广泛中和抗体 (bnAb) 前体和成熟的bnAbs对HIV-1包膜 (Env) 外围区域 (MPER) 的诱导.
评估这种方法在快速开发艾滋病毒疫苗方面的潜力.

主要方法:

在HVTN 133临床试验 (NCT03934541) 中使用了/脂质体免疫原.
这项研究重点是针对HIV-1 Env MPER的B细胞系.
分析包括评估诱导抗体的中和范围和强度,并确定关键突变.

主要成果:

该MPER脂体免疫原成功诱导了多克隆HIV-1B细胞系,包括前体和成熟的bnAbs.
在两次免疫接种后,最强的抗体中和了全球2级HIV-1菌株的15%和B类菌株的35%.
疫苗诱导的选择有利于不太可能的突变增强抗体与gp41和脂质的结合,促进中和.

结论:

这项研究提供了具有异质中和活性的人类B细胞系的快速疫苗诱导概念的证明.
结果表明成功选择了抗体不太可能的突变,从而提高了中和效率.
这种方法提供了一种可行的策略,并为成功开发HIV-1疫苗提供了一条道路.

更多相关视频

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

相关概念视频

B Cell Activation and Differentiation

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...